<DOC>
	<DOCNO>NCT00404326</DOCNO>
	<brief_summary>The current standard locally advanced cervical cancer concurrent cisplatin-based chemotherapy , however , treatment result need improve . Epigenetic aberration play important role cancer progression silence growth regulatory gene evidence inhibitor DNA methylation HDAC inhibition synergize radiation chemotherapy effect . Objective . To determine response rate , safety biological effect hydralazine magnesium valproate add cisplatin chemoradiation . Hypothesis . Hydralazine magnesium valproate associate chemoradiation increase clinical complete response rate 95 % compare 75 % see historical control treat cisplatin chemoradiation FIGO stage IIIB patient . Metodology . A total 17 FIGO stage IIIB patient histologically confirm cervical carcinoma previous treatment include . Patients type acetylator status receive either 182 83 mg hydralazine , magnesium valproate 40mg/Kg day -7 end chemoradiation ( external brachytherapy ) . Clinical response rate , safety transcriptome change analyze .</brief_summary>
	<brief_title>Hydralazine Valproate Plus Cisplatin Chemoradiation Cervical Cancer</brief_title>
	<detailed_description>Eligible patient sign informed consent undergo study evaluation type acetylator phenotype receive either 182 83 mg hydralazine , magnesium valproate 30mg/Kg day -7 end chemoradiation ( external brachytherapy . External beam radiation deliver megavoltage equipment dose 50gy ( 2Gy fraction monday friday ) concurrently cisplatin 40mg/m2 six week . Within one two week , intracavitary brachytherapy ( low-dose rate , Cesium source ) deliver achieve least 85Gy point A . A punch biopsy primary tumor take enter study day 8 hydralazine valproate treatment ( first dose cisplatin radiation ) ass global gene expression profile microarray analysis . Blood sample take assess global DNA methylation , histone deacetylase activity plasma level hydralazine valproic acid . Clinical response toxicity assess .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>informed consent , histological diagnosis cervical carcinoma ( epidermoid , adenoesquamous adenocarcinoma ) , clinical stage III B , untreated , aged 1870 year , performance status 02 accord ECOG classification , adequate liver , hematological renal function , define : hemoglobin &gt; 10 g/L , leukocytes &gt; 4000/mm3 , platelet &gt; 100 000mm3 ; normal creatinine value creatinine clearance &gt; 60 mL/min ; total bilirubin &lt; 1.5 upper normal limit value ; evidence systemic disease paraaortic lymph node involvement . History allergy hydralazine valproate ; past present condition rheumatic disease , central nervous system disease , heart failure aortic stenosis postural hypotension diagnose physician ; previous use experimental drug ( hydralazine magnesium valproate ) well patient pregnant breastfeeding . Other exclusion criterion include uncontrolled systemic disease infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Cervical carcinoma</keyword>
	<keyword>Epigenetic therapy</keyword>
	<keyword>Hydralazine</keyword>
	<keyword>Valproate</keyword>
	<keyword>Microarray analysis</keyword>
</DOC>